News Articles

Boehringer Ingelheim and Lilly announce Trajenta®’s CARMELINA® cardiovascular outcome trial met its... INGELHEIM, Germany & INDIANAPOLIS, Ind. -Thursday 19 July 2018  

(BUSINESS WIRE)-- CARMELINA®1 (CArdiovascular safety and Renal Microvascular outcomE with LINAgliptin in patients with type 2 diabetes at high vascular risk) met its primary endpoint, defined as time to first occurrence of cardiovascular death, non-fatal myocardial infarction or non-fatal...

Boehringer Ingelheim Invests More Than €200 Million to Establish Strategic Production Center for Veterinary Public... -Tuesday 10 July 2018

(BUSINESS WIRE)-- Boehringer Ingelheim today announced an investment of more than €200 million into a new strategic production center for Veterinary Public Health. The company will establish the new site in the French Rhône-Alpes region, which is known as the European “vaccine valley”....

CHMP issues positive opinion to expand Jardiance®, Synjardy® and... -Monday 2 July 2018  

European labels for Jardiance®, Synjardy® and Glyxambi® expanded to include positive effects on cardiovascular and renal endpoints from landmark EMPA-REG OUTCOME® trial1 (BUSINESS WIRE) -- Boehringer Ingelheim and Eli Lilly and Company (NYSE:LLY) announced today that the European...

Boehringer Ingelheim and Lilly announce positive top-line Phase III data results for empagliflozin as adjunct to insulin... -Monday 25 June 2018  

(BUSINESS WIRE) -- Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today announced that both randomised controlled trials in the EASE phase III programme, investigating the use of empagliflozin in combination with insulin therapy in adults with type 1 diabetes, met their primary...

Boehringer Ingelheim bolsters biologics research and development with 230 million euro investment in new development... -Friday 22 June 2018

(BUSINESS WIRE)-- Today Boehringer Ingelheim announced a 230 million euro investment into a new Biologicals Development Center (BDC) at the company’s Research and Development site in Biberach, Germany during the foundation stone laying for the new center. “The BDC is another key building...

Spiolto® Respimat® enables greater physical activity in people living with... -Wednesday 23 May 2018    

Data presented at American Thoracic Society meeting underpin the benefits of Spiolto® Respimat® for physical activity in COPD1,2 Study published in American Journal of Respiratory and Critical Care Medicine shows Spiolto® Respimat® improves exercise capacity in...

Efficacy and safety of OFEV® reinforced in new presentations at ATS 2018 -Tuesday 22 May 2018

New analysis of the INPULSIS® and TOMORROW trials suggests treatment with OFEV® (nintedanib) associated with reduced risk of death in patients with idiopathic pulmonary fibrosis Separate analysis of INPULSIS® trials showed association between lung function decline and worsening in...

Boehringer Ingelheim R&D Pushes to Transcend Disease Boundaries -Wednesday 25 April 2018

Promising first-in-class and potential medical breakthrough pipeline projects presented at R&D Press Conference 80 clinical and pre-clinical projects of which 65% have first-in-class and breakthrough potential Highlight: First-in-class monoclonal antibody shows potential in multiple...

Boehringer Ingelheim and Lilly Announce an Academic Collaboration with University of Oxford to Investigate the Effects... -Monday 16 April 2018  

(BUSINESS WIRE) -- Boehringer Ingelheim and Eli Lilly and Company (NYSE:LLY) today announced an academic collaboration with the University of Oxford. EMPA-KIDNEY will investigate the effects of empagliflozin on the progression of kidney disease and the occurrence of cardiovascular death, in...

Boehringer Ingelheim to invest €65 million in avian vaccines -Thursday 12 April 2018  

(BUSINESS WIRE) -- Six months after inaugurating its new French animal health headquarters in the heart of the Lyon-Gerland Biodistrict, Boehringer Ingelheim has confirmed its allegiance to the region by announcing that it is about to invest a further €65 million in the metropolitan...

Boehringer Ingelheim and OSE Immunotherapeutics Announce Global Immuno-Oncology Partnership to Develop a Pioneering... -Thursday 5 April 2018

(BUSINESS WIRE) -- Boehringer Ingelheim and OSE Immunotherapeutics, a biotechnology company focused on the development of innovative immunotherapies, today announced a collaboration and exclusive worldwide collaboration and license agreement to jointly develop OSE-172, a SIRP-alpha antagonist...

Final results from landmark DYNAGITO® trial published in The Lancet Respiratory... -Thursday 29 March 2018      

Results enhance existing evidence base showing Spiolto® Respimat® improves symptom reduction and quality of life over Spiriva® Respimat®2,3,4,5,6 For media excluding the United States of America, Canada and the United Kingdom (BUSINESS WIRE) -- Boehringer Ingelheim today...

Three Leading Animal Health Companies Join Hands to Launch World-Class Vaccine Joint Venture Targeting Foot-and-Mouth... -Monday 26 March 2018

(BUSINESS WIRE) -- Shaanxi Meili Omni-Honesty Animal Health Co., Ltd., China’s world-class vaccine company targeting foot-and-mouth disease in swine, was launched on March 24th with a groundbreaking ceremony held at the Airport New City in Xi’an, capital city of Shaanxi Province. Meili...

Favorable safety profile of Pradaxa® (dabigatran etexilate) confirmed in large prospective real-world... -Tuesday 20 March 2018  

Complete Phase II results from the prospective GLORIATM-AF registry in dabigatran patients presented as a late-breaker at the EHRA 2018, the annual congress of the European Heart Rhythm Association (EHRA)1 Low rates of major bleeding and stroke observed for dabigatran patients1 Long-term...

FDA grants Fast Track designation to nintedanib for the treatment of systemic sclerosis with associated interstitial... -Monday 19 March 2018

Fast Track designation facilitates development of new therapies that treat serious conditions and fulfill an unmet medical need The designation is based on the Investigational New Drug Application for SSc-ILD and the anticipated efficacy and safety data from the Phase III SENSCIS™...

Boehringer Ingelheim and Lilly expand heart failure programme for empagliflozin with new exercise capacity trials -Tuesday 6 March 2018  

  EMPERIAL clinical trials will evaluate the effect of empagliflozin on exercise ability and heart failure symptoms in people with chronic heart failure1,2 EMPERIAL is part of the most comprehensive clinical trial programme of an SGLT2 inhibitor in chronic heart...

Boehringer Ingelheim Starts New Campaign: ‘Why wait in IPF?’ -Wednesday 28 February 2018

Rare Disease Day draws attention to the importance of early diagnosis and treatment of IPF. Even though international guidelines recommend to offer antifibrotic treatment to the majority of individuals with IPF, research in Europe shows that around 40% of patients with confirmed IPF do not...

Boehringer Ingelheim Demonstrates Continuous Commitment to Its Venture Fund and Fostering Innovation by More than... -Wednesday 3 January 2018

(BUSINESS WIRE)-- Boehringer Ingelheim today announced an increase in funding for its corporate venture fund, known as the Boehringer Ingelheim Venture Fund (BIVF), from EUR 100 to 250 million. The additional funds will be used to invest in promising early stage start-up companies, focusing on...

Boehringer Ingelheim Marks Great Progress in Immuno-oncology Research Partnerships in 2017 -Monday 11 December 2017

(BUSINESS WIRE)-- 2017 marks a year of significant advancement for Boehringer Ingelheim as it secured a range of external partnerships with the goal of transforming the lives of patients and winning the fight against cancer. External partnerships complement Boehringer Ingelheim’s two-pronged...

Key sub-analyses of RE-DUAL PCI™ showed large reductions in the incidence of bleeding complications if... -Wednesday 15 November 2017  

Dual therapy with dabigatran consistently favourable across key sub-groups in atrial fibrillation patients following PCI with stent placement Benefits shown in sub-group analyses were consistent with overall results of the trial Data presented at AHA Scientific Sessions 2017 reinforce...